课题基金 / 基金详情

A Manganese Alternative to Gadolinium for MRI

A Manganese Alternative to Gadolinium for MRI
用于 MRI 的钆的锰替代品
批准号:
9165529
负责人:
Eric Michael Gale
金额:
$21.34万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-08-01 至 2018-05-31

项目摘要

项目成果

Eric Michael Gale的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要/摘要 慢性肾脏疾病(CKD)困扰着14%的美国成年人,是面临的首要挑战 公共卫生。慢性肾脏病患者的合并症患病率更高,2010年估计为17% 医疗保险成本直接归因于CKD患者的医疗保健。病人管理进一步混乱 通过禁止使用常规用于计算机断层扫描的静脉造影剂 (CT)和磁共振成像(MRI)扫描,医生依靠这些扫描来诊断 血管和软组织的结构和灌流。合并症的患病率及其相关风险 使用造影剂后,两者均随肾功能降低而增加。因此,随着患者变得越来越脆弱 医生被迫在有限的放射学信息下做出关键的患者管理决策。 含碘的CT造影剂会对肾功能受损的患者造成急性不可逆转的肾损伤, 称为造影剂肾病(CIN)。磁共振造影剂中使用的Gd直接与 肾损害患者的肾源性系统性纤维化(NSF)。 我们假设,合理设计的锰络合物可以提供Gd的MR对比剂,即 适用于肾功能受损患者。合理的分子设计可以促进磁弛豫, 限制锰的释放,促进非肾脏清除和全身彻底消除。此外,Mn是 生物来源的和游离的Mn2+通过胆道快速排出。如果发生少量的锰释放, 游离离子会被结合到内源不稳定的锰库中,或者以其他方式被排出。 我们发明了一种设计合理的锰基造影剂,称为Mn-PYC3A,它可以提供弛豫性能 相当于临床使用的Gd造影剂,解离速度比临床使用的慢20倍 并通过混合的肾和肝胆途径进行快速的全身清除。在这 我们将准备一个小型的、有重点的Mn-PyC3A衍生物库,以优化疗效和安全性 这种替代造影剂的性质。我们将在体外对这些锰络合物进行表征 松弛、稳定性和细胞毒性。然后我们将在小鼠身上进行试点研究,以评估体内的疗效, 生物分布和清除。稳定、高弛豫度的锰络合物将在小鼠癌症模型中进行评估 并与临床使用的Gd对比剂进行比较。对于锰-螯合物来说,显示出肿瘤的最佳组合 增强、全身消除和体内稳定性,我们将在正常情况下评估急性剂量毒代动力学 在大鼠和肾功能受损的大鼠中。这项工作的结果将是经过验证的Gd的替代方案,即 准备进行研究新药应用和临床翻译。
英文摘要
Project Summary/ Abstract Chronic kidney disease (CKD) afflicts 14% of the US adults and represents a foremost challenge facing public health. CKD patients suffer a higher prevalence of co-morbidities and an estimated 17% of 2010 Medicare costs were directly attributable to CKD patient healthcare. Patient management is further confounded by contraindications against the use of intravenous contrast media routinely used with computed tomography (CT) and magnetic resonance imaging (MRI) scans that physicians rely upon to diagnose irregularities in the structure and perfusion of vasculature and soft tissue. The prevalence of co-morbidities and the risk associated with contrast media both increase with decreased renal function. Thus as patients grow increasingly vulnerable physicians are forced to make key patient management decisions with limited radiologic information. Iodinated CT contrast media can cause acute and irreversible kidney injury to renally impaired patients, termed contrast-induced nephropathy (CIN). Gadolinium (Gd) used in MR contrast media is directly linked to nephrogenic systemic fibrosis (NSF) in renally impaired patients. We hypothesize that rationally designed Mn-chelates can provide an MR contrast alternative to Gd that is compatible for use in renally impaired patients. Rational molecular design can promote magnetic relaxation, limit Mn release, and promote non-renal clearance and complete whole body elimination. Furthermore, Mn is biogenic and free Mn2+ is rapidly excreted via the biliary pathway. Should a small amount of Mn release occur, dissociated ions would be incorporated within the endogenous labile Mn pool, or otherwise be excreted. We invented a rationally designed Mn-based contrast agent, termed Mn-PyC3A, that provides relaxivity equivalent to clinically used Gd contrast agents, dissociates 20x more slowly than the clinically used Magnevist, and undergoes rapid, whole body clearance via mixed renal and hepatobiliary paths. In this proposal we will prepare a small, focused library of Mn-PyC3A derivatives to optimize the efficacy and safety properties of this alternate contrast agent. We will characterize these Mn-chelates in vitro with respect to relaxivity, stability, and cell toxicity. We will then perform pilot studies in mice to evaluate in vivo efficacy, biodistribution and clearance. Stable, high relaxivity Mn-chelates will be evaluated in mouse models of cancer and compared with clinically used Gd contrast. For the Mn-chelate that shows the best combination of tumor enhancement, whole body elimination, and in vivo stability, we will evaluate acute dose toxicokinetics in normal rats and in rats with impaired renal function. The output of this work will be a validated alternative to Gd that is poised for an investigational new drug application and clinical translation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Variable-Field Nuclear Magnetic Relaxometer
  • 批准号:
    10630565
  • 项目类别:
  • 资助金额:
    $41.8万
  • 财政年份:
    2023
  • 负责人:
    Eric Michael Gale
  • 依托单位:
A New Paradigm for Iron Replacement Therapy
  • 批准号:
    10715655
  • 项目类别:
  • 资助金额:
    $65.34万
  • 财政年份:
    2023
  • 负责人:
    Eric Michael Gale
  • 依托单位:
Noninvasive Nephritis Imaging
  • 批准号:
    10490328
  • 项目类别:
  • 资助金额:
    $25.08万
  • 财政年份:
    2021
  • 负责人:
    Eric Michael Gale
  • 依托单位:
Noninvasive Nephritis Imaging
  • 批准号:
    10373279
  • 项目类别:
  • 资助金额:
    $20.88万
  • 财政年份:
    2021
  • 负责人:
    Eric Michael Gale
  • 依托单位:
海外基金